Xarelto

Type: Product
Name: Xarelto
First reported 9 hours ago - Updated 9 hours ago - 1 reports

Prescription Drug Sales Expected to Exceed $1 Trillion by End of Decade

A surge of patent expirations is predicted to drive annual growth .Worldwide prescription drug sales are predicted to pass the $1 trillion mark by the year 2020, according to estimates by EvaluatePharma in the 7th edition of its World Preview report.The ... [Published Pharmacy Times - 9 hours ago]
First reported Jul 31 2014 - Updated Jul 31 2014 - 2 reports

Xarelto has defied commercial expectations, particularly regarding how it has fended off competition

(live-PR.com) - Last week, analysts identified Bayer and Johnson & Johnson´s anticoagulant Xarelto as the industry´s leading product-level sales growth driver in 2013. Furthermore, in announcing its Q4 results, Bayer increased its own peak revenue forecast ... [Published Live-PR.com - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 31 2014 - 3 reports

Possible Lawsuit: Bayer Facing Lawsuits over Xarelto Bleeding Events

Home Page >> Potential Lawsuit >> Bayer Facing Lawsuits over Xarelto Bleeding EventsLos Angeles, CA: Bayer AG and Janssen, the makers of Xarelto (Rivaroxaban) EI, are facing a wrongful death lawsuit recently filed by the family of a man ... [Published Lawyers & Settlements - Jul 31 2014]
Entities: Xarelto, Bayer AG, Lawsuit
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

NAPSR news: Bayer Healthcare retains positive Q2 report from pharmaceutical sales

- Jul. 30, 2014 - WASHINGTON, D.C. -- The Bayer Group has reported an increase in profits compared to last year based on their 2014 Q2 Report. Net income rose 13.3%to 953 million euros ($1.27 billion) while worldwide sales amounted to 10.5 billion euros ... [Published Prlog - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 4 reports

UPDATE 2-Bayer's new drug boost dampened by strong euro

11:52am BST* Q2 adj EBITDA 2.22 bln euros vs 2.31 bln poll avg* Sees 41 bln euros in 2014 sales vs 41-42 bln previously* Shares up 3 pct as outlook for adjusted EBITDA reaffirmed (Adds analyst quote, updates shares)By Ludwig BurgerFRANKFURT, July 30 (Reuters) ... [Published Reuters UK - Jul 30 2014]
Entities: Bayer AG, Drugs, Xarelto, EBITDA
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Bayer nabs new OKs for Eylea, Stivarga as top meds skate past forecasts

In March, Bayer CEO Marijn Dekkers boldly predicted that the company's 5 new drugs--including the blood thinner Xarelto and the macular degeneration treatment Eylea--would help his company achieve 8% annual sales growth through 2016. Judging from the ... [Published FiercePharma - Jul 30 2014]
Entities: Bayer AG, Eylea, Stivarga
First reported Jul 29 2014 - Updated Jul 30 2014 - 4 reports

Acute coronary syndrome treatment market to more than triple by 2023

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023.According to research and consulting ... [Published Pharma Letter - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

BAYER : Profit Rises But Outlook Tweaked By Euro Strength

FRANKFURT-- Bayer AG's second-quarter net profit increased 14%, helped by robust demand for its latest drugs and crop protection products, but the German company tweaked its full-year outlook to reflect the strength of the euro against other currenci ... [Published 4 Traders - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Bayer Second-Quarter Earnings Rise on Sales of New Medicines

July 30 (Bloomberg) -- Bayer AG’s second-quarter earnings rose 1 percent as growth in new medicines offset the effect of a strengthening euro on margins at the German company’s crop and plastics units.Earnings before interest, taxes, depreciation, amortization ... [Published Washington Post - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Xarelto Lawsuits Information Website Launched by Rottenstein Law Group LLP

Rockville Centre, NY -- ( SBWIRE ) -- 07/28/2014 -- The new site, www.xareltoinjuryfirm.com , offers comprehensive information about the severe adverse side effects associated with Xarelto. Like similar so-called “blood thinners” (anticoagulants), Xarelto ... [Published SBWire - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

People’s Pharmacy: Doctor’s dirty hands drive patient away

MyMy husband asked his doctor to please wash his hands before examining him. The doctor’s reply was “What for?” He washed his hands (poorly) and threw the towel into the sink.At a follow-up appointment, he was talking to me about my treatment. He came ... [Published Buffalo News - Jul 28 2014]
Entities: pharmacy, Xarelto, SPLEEN, Emsam
First reported Jul 27 2014 - Updated Jul 27 2014 - 1 reports

Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa

The Institute of Safe Medication Practices (ISMP) Found that the number of serious adverse events such as Xarelto bleeding side-effects reported after the use of the Xarelto blood thinner has now out numbered the complaints filed for its competitor Pradaxa, ... [Published Bio-Medicine - Jul 27 2014]

Quotes

..."We live in an age when corporations have more power, and seem to have more rights, than real people," Mr. Radigan said. "The Courts sometimes think corporations are people, but I have my doubts. I prefer representing real people. I find nothing more satisfying than helping real people win their disputes against uncaring corporations" Mr. Radigan added
...5 billion euros ($14 billion). Primary growth was a result of the company’s pharmaceuticals division. "Our life science businesses, in particular, saw unabated growth momentum, with very encouraging sales gains for our recently launched pharmaceutical products and our North and Latin American Crop Science business" Chief Executive Marijn Dekkers said in a statement. According to the company, the pharmaceuticals Sector grew by 10% (Fx & portfolio adj...
Such strong performance from Bayer's new drugs is helping cushion the blow of currency fluctuations, analysts say. "It's mainly thanks to the good development of new pharma products that Bayer achieved slight gains in sales and earnings in Q2 2014 despite the persistent strain from foreign exchange rates" Nord LB analyst Thorsten Strauss told Reuters. Strauss maintains a "buy" rating on the company
Sales of the Bayer HealthCare business unit rose in the second quarter by 0.9% (Fx & portfolio adj 6.3%) to 4.85 billion euros "This growth continued to be driven by our recently launched pharmaceutical products, while sales at Consumer Health were only slightly above the prior-year period" Dr Dekkers commented. Sales showed above-average development in the Emerging Markets, he noted

More Content

All (162) | News (132) | Reports (0) | Blogs (26) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Prescription Drug Sales Expected to Exceed $1 T... [Published Pharmacy Times - 9 hours ago]
Michael G. Radigan Joins The JTB Law Group, LLC [Published TVNewsCheck - Aug 01 2014]
Xarelto has defied commercial expectations, par... [Published Live-PR.com - Jul 31 2014]
Analysts identified Bayer and Johnson & Johnson... [Published Live-PR.com - Jul 31 2014]
Bayer's (BAYRY) CEO Marijn Dekkers on Q2 2014 R... [Published Seeking Alpha - Jul 31 2014]
Possible Lawsuit: Bayer Facing Lawsuits over Xa... [Published Lawyers & Settlements - Jul 31 2014]
Xarelto Lawsuit Alleges Man’s Death from Uncont... [Published Bio-Medicine - Jul 30 2014]
Portola Pharmaceuticals to Announce Second Quar... [Published Tamar Securities - Jul 30 2014]
Xarelto Lawsuit Alleges Man’s Death from Uncont... [Published PRWeb - Jul 30 2014]
NAPSR news: Bayer Healthcare retains positive Q... [Published Prlog - Jul 30 2014]
Bayer nabs new OKs for Eylea, Stivarga as top m... [Published FiercePharma - Jul 30 2014]
Bayer’s 2nd-qtr earnings hit by currency, missi... [Published Pharma Letter - Jul 30 2014]
Acute coronary syndrome treatment market to mor... [Published Pharma Letter - Jul 30 2014]
UPDATE 2-Bayer's new drug boost dampened by str... [Published Reuters UK - Jul 30 2014]
New blockbuster drugs to create massive future ... [Published Pharma Field - Jul 30 2014]
BAYER : Profit Rises But Outlook Tweaked By Eur... [Published 4 Traders - Jul 30 2014]
Bayer's prescription drug sales rise 10 percent... [Published FirstWord Pharma - Jul 30 2014]
Bayer Q2 Profit Rises 13% [Published RTTNews.com - Jul 30 2014]
BAYER : results fall slightly short of view on ... [Published 4 Traders - Jul 30 2014]
Bayer Second-Quarter Earnings Rise on Sales of ... [Published Washington Post - Jul 30 2014]
Medicines update (13) [Published Pharmacy News - Jul 30 2014]
Rivaroxaban Beats Injectable on Cost-Effectiveness [Published Pharmacy Practice News - Jul 30 2014]
Apixaban (Eliquis) Approved in Europe for DVT, PE [Published Diabetes Care - Jul 29 2014]
New blockbuster drugs to more than triple acute... [Published European Pharmaceutical Review - Jul 29 2014]
New "Blockbusters" Will Triple Acute Coronary S... [Published Pharmaceutical Executive - Jul 29 2014]
Premature infants have increased blood clot ris... [Published Examiner.com - Jul 28 2014]
Xarelto Lawsuits Information Website Launched b... [Published SBWire - Jul 28 2014]
People’s Pharmacy: Doctor’s dirty hands drive p... [Published Buffalo News - Jul 28 2014]
Xarelto Lawsuit News: Report Finds Adverse Even... [Published Bio-Medicine - Jul 27 2014]
3 Future Biotechnology Blockbusters? [Published Motley Fool Discussion Boards - Jul 26 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Physicians in Brazil and Mexico Ideally Prefer ... [Published PR Newswire: General Business - Jul 23 2014]
BURLINGTON, Mass., July 23, 2014 /PRNewswire/ -- Decision Resources Group finds that novel oral anticoagulants (NOACs) such as Xarelto, Boehringer Ingelheim's Pradaxa and Bristol-Myers Squibb/Pfizer's Eliquis are preferred treatments for venous thromboembolism ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 11 2014]
Bayer faces law suits in United States over Xar... [Published Yahoo! Health News - Jun 14 2014]
Germany's Bayer AG faces its first law suits in the United States over anti-clotting drug Xarelto, one of its top five medicines, the Frankfurter Allgemeine Zeitung newspaper reported on Saturday, citing company sources. A Bayer spokesman dec... ...
Top stories in health and medicine, June 10, 2014 [Published KevinMD.com - Jun 10 2014]
From  MedPage Today : AMA Mulls Gun Violence CME . As the AMA’s House of Delegates was meeting in a downtown hotel here, 29 local residents were shot and four killed within a 10-mile radius. Most Breast Ca Patients Fall Short on Exercise . Two-thirds ...
Cardio Notes: Xarelto for Seniors, Carotid Sten... [Published MedPageToday.com - medical news plus CME for ph ... - Jun 09 2014]
(MedPage Today) -- Rivaroxaban (Xarelto) matched warfarin in both older and younger patients. Also, the risk of dying in the month after carotid artery stenting varied to a large extent across U.S. hospitals. ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Keller Rohrback L.L.P. Investigates Allegations... [Published GlobeNewswire: Acquisitions News - Jul 23 2014]
Portola Pharmaceuticals Enters Into Clinical Co... [Published GlobeNewswire: Earnings News - Feb 03 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.